Evidence map›Paper›PMID 39524037›Full record

ArticleCurrent research in toxicology2024

Cytotoxicity and inhibitory potential of CUDC-101 in non-small cell lung cancer cells with rare EGFR L861Q mutation.

Chunhong Chu, Huixia Xu, Chenxue Liu, Xiangkai Wei, Lanxin Li, Rui Wang, Wenrui Cui, Guoliang Zhang, Chenyang Liu, Ke Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current research in toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chunhong ChuTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Huixia XuTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Chenxue LiuTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Xiangkai WeiTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Lanxin LiTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Rui WangTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Wenrui CuiTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Guoliang ZhangTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Chenyang LiuTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Ke WangTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Lei AnTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.
Fei HeTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidermal growth factor receptor (EGFR) represents an effective target for the treatment of non-small cell lung cancer. In the treatment of classical EGFR mutations, EGFR tyrosine kinase inhibitors have achieved desirable clinical efficacy. However, the effectiveness of tyrosine kinase inhibitors (TKIs) against the L861Q mutation has not been fully established. In this study, the four cell lines containing the L861Q mutation were constructed by CRISPR and the anti-tumour effects of CUDC-101 on them were investigated in vitro by various chemosensitivity methods, with afatinib serving as a positive control. The results demonstrated that CUDC-101 inhibited the proliferation and clonogenic capacity on the four cells through the ERK or AKT pathways, decreased the mitochondrial membrane potential of the cells, blocked the cell cycle and promoted apoptosis. Our findings suggest that CUDC-101 may be a promising treatment option for NSCLC patients with the EGFR exon 18 substitution mutation L861Q.

Indexed as

CUDC-101CytotoxicologyL861QMutationProliferation

Identifiers

PMID39524037
PMCPMC11546682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.